Engineered Immune Cells Targeting KRAS Cancer Mutations Show Potent Tumor-Killing Ability

Researchers isolated a natural human TCR (TCR0) from T cells that recognized HLA-A*11:01-presented KRAS G12V8-16 peptides. Finding TCR0 insufficient for tumor killing, they generated an avidity-optimized mutant (TCR3). TCR3-transduced T cells were tested against tumor cell lines in vitro for cytotoxicity, specificity, and resistance to immunosuppressive factors. In vivo efficacy was evaluated in tumor-bearing animal models, assessing tumor clearance and immune cell infiltration.

KRAS mutations drive roughly 25% of all human cancers, yet no approved immunotherapy directly targets KRAS neoantigens. This study demonstrates that engineering T-cell receptors for higher avidity can overcome the weak immune responses typically seen against KRAS, while also addressing tumor immune-escape mechanisms that have stymied other approaches.

TCR-T cell therapy is an emerging form of adoptive cell therapy that complements CAR-T approaches. While CAR-T has succeeded in blood cancers, solid tumors remain challenging. Targeting KRAS neoantigens with avidity-optimized TCRs represents a precision strategy for some of the hardest-to-treat solid cancers, including pancreatic, colorectal, and lung cancers where KRAS G12V mutations are prevalent.

No human clinical trial data are presented — results are from in vitro experiments and animal models. The therapy is restricted to HLA-A*11:01-positive patients (roughly 15–20% of the global population), limiting generalizability. Long-term safety, persistence of TCR3-T cells, and potential off-target toxicity in humans remain to be determined.